| Overview |
| bs-13146R |
| TRRAP Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human, Rat, Xenopus laevis |
| Mouse, Dog, Sheep, Pig, Horse, Chicken |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TRRAP |
| 3401-3600/3859 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 8295 |
| Nucleus |
| 350/400 kDa PCAF associated factor; FLJ10671; PAF 350/400; PAF 400; PAF350/400; PAF400; STAF 40; STAF40; TR AP; Tra 1; Tra1; Tra1 homolog; Transactivation / transformation domain associated protein; Transactivation/transformation domain associated protein; Transformation/transcription domain associated protein; TRAP; TRRAP_HUMAN. |
| The transcription factors c-Myc and E2F are involved in regulating cell cycle progression. Overexpression of c-Myc in certain cell types induces noncycling cells to enter the cell cycle via a mechanism involving E2F-1 (1). E2F-1 is thought to regulate c-Myc expression via interactions with the retinoblastoma protein (2). TRRAP (for transformation/transcription domain-associated protein) interacts specifically with both c-Myc and E2F-1. Expression of trans-activated mutant TRRAP inhibits the oncogenic transformation of both c-Myc and E2F-1, suggesting that TRRAP is required for these oncogenic transcription factor pathways (3). TRRAP shares homology with the ATM/PI 3-kinase family, and it is highly conserved in evolution (4,5). |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz